Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Omeros Announces Presentation Detailing Narsoplimab Compassionate Use
Omeros Announces Additional Royalty Monetization with DRI Healthcare Trust
Omeros Corporation Reports Third Quarter 2023 Financial Results
Omeros to Announce Third Quarter Financial Results on November 9, 2023
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
Oct 16 (Reuters) - Omeros Corp (OMER.O) said on Monday it will discontinue development of an experimental therapy to treat a type of kidney disease after a late-stage study failure and allocate its resources to other research studies.
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy